A5030102466- Pancreatic and Hepatic Oncology Research
- MicroRNA in disease regulation
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- Extracellular vesicles in disease
- Cancer-related molecular mechanisms research
- Gastrointestinal Tumor Research and Treatment
- Pediatric Hepatobiliary Diseases and Treatments
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Pancreatitis Pathology and Treatment
- Immune cells in cancer
- RNA modifications and cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Cells and Metastasis
- Neuroendocrine Tumor Research Advances
- Inflammatory Biomarkers in Disease Prognosis
- Single-cell and spatial transcriptomics
- Cancer Mechanisms and Therapy
- Intestinal Malrotation and Obstruction Disorders
- Health Services Management and Policy
- Advanced biosensing and bioanalysis techniques
- Colorectal Cancer Screening and Detection
- Caveolin-1 and cellular processes
- Phagocytosis and Immune Regulation
Amsterdam University Medical Centers
2018-2024
Cancer Center Amsterdam
2017-2024
Vrije Universiteit Amsterdam
2022-2024
Erasmus MC
2022-2024
Dutch Cancer Society
2023
Amphia Ziekenhuis
2023
Amsterdam UMC Location Vrije Universiteit Amsterdam
2015-2022
University Medical Center
2021
Netherlands Comprehensive Cancer Organisation
2021
National Enterprise for NanoScience and NanoTechnology
2016
Blood-based liquid biopsies, including tumor-educated blood platelets (TEPs), have emerged as promising biomarker sources for non-invasive detection of cancer. Here we demonstrate that particle-swarm optimization (PSO)-enhanced algorithms enable efficient selection RNA panels from platelet RNA-sequencing libraries (n = 779). This resulted in accurate TEP-based early- and late-stage non-small-cell lung cancer 518 validation cohort, accuracy, 88%; AUC, 0.94; 95% CI, 0.92–0.96; p < 0.001; n 106...
Cancer patients benefit from early tumor detection since treatment outcomes are more favorable for less advanced cancers. Platelets involved in cancer progression and considered a promising biosource detection, as they alter their RNA content upon local systemic cues. We show that tumor-educated platelet (TEP) RNA-based blood tests enable the of 18 types. With 99% specificity asymptomatic controls, thromboSeq correctly detected presence two-thirds 1,096 samples stage I–IV half 352 I–III...
Objective: The aim of the study was to identify plasma microRNA (miRNA) biomarkers for stratifying and monitoring patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) treated FOLFIRINOX, investigate their functional roles. Summary Background Data: FOLFIRINOX has become a standard therapy PDAC can be used potentially downstage disease. However, only subset respond, guide decision-making are urgently needed. Methods: We microarray-based profiling discover...
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a relative paucity of cancer cells that are surrounded an abundance nontumor and extracellular matrix, known as stroma. The interaction between stroma contributes to poor outcome, but how proteins from these individual compartments drive aggressive tumor behavior not known. Here, we report the proteomic analysis laser-capture microdissected (LCM) PDAC samples. We isolated stroma, tumor, bulk samples cohort with long- short-term...
Abstract Background Minimally invasive diagnostic biomarkers for patients with pancreatic ductal adenocarcinoma (PDAC) and distal cholangiocarcinoma (dCCA) are warranted to facilitate accurate diagnosis. This study identified plasma proteins based on proteomics of tumor secretome. Materials Methods Secretome normal tissue was collected after resection PDAC dCCA. Differentially expressed were measured by mass spectrometry. Selected candidate carbohydrate antigen 19-9 (CA19-9) validated...
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies with a 5-year survival rate only 9%. Despite fact that changes in glycosylation patterns during tumour progression have been reported, no systematic approach has conducted to evaluate its potential for patient stratification. By analysing publicly available transcriptomic data samples and cell lines, we identified here two specific glycan profiles PDAC correlated progression, clinical outcome epithelial...
Introduction: Pancreatic cancer is a complex disease, with an extremely poor response to chemotherapy. Emerging evidence indicates that the tumor microenvironment (TME) might play important role in mediating chemoresistance. Areas covered: The evaluated study by Geller and collaborators describes several bacterial species within pancreatic tissues TME investigated their roles gemcitabine Intratumor bacteria express enzyme cytidine deaminase (CDD), whose long form (CDDL) was shown metabolize...
Distinction of pancreatic ductal adenocarcinoma (PDAC) in the head pancreas, distal cholangiocarcinoma (dCCA), and benign periampullary conditions, is complex as they often share similar clinical symptoms. However, these diseases require specific management strategies, urging improvement non-invasive tools for accurate diagnosis. Recent evidence has shown that ratio between CA19-9 bilirubin levels supports diagnostic distinction or malignant hepatopancreaticobiliary diseases. Here, we...
Pancreatic ductal adenocarcinoma (PDAC) is traditionally associated with thrombocytosis/hypercoagulation and novel insights on platelet-PDAC “dangerous liaisons” are warranted. Here we performed an integrative omics study investigating the biological processes of mRNAs expressed miRNAs, as well proteins in PDAC blood platelets, using benign disease a reference for inflammatory noise. Gene ontology mining revealed enrichment RNA splicing, mRNA processing translation initiation miRNAs but...
Accurate risk prediction models using routinely measured biomarkers-eg, carbohydrate antigen 19-9 (CA19-9) and bilirubin serum levels-for pancreatic cancer could facilitate early detection of prevent potentially unnecessary diagnostic tests for patients at low risk. An externally validated model CA19-9 levels in a larger cohort with or benign periampullary diseases is needed.To assess the discrimination, calibration, clinical utility readily available blood biomarkers (carbohydrate [CA19-9]...
Accurate diagnosis of pancreatic head lesions remains challenging as no minimally invasive biomarkers are available to discriminate distal cholangiocarcinoma (CCA) from ductal adenocarcinoma (PDAC). The aim this study is identify specific circulating microRNAs (miRNAs) diagnose CCA. In the discovery phase, PCR profiling 752 miRNAs was performed on fourteen patients with CCA and age- sex-matched healthy controls. Candidate were selected for evaluation validation by RT-qPCR in an independent...
This study examined the composition of immune microenvironment at different sites within resected pancreas specimens from patients with pancreatic ductal adenocarcinoma (PDAC). Therefore, single-cell suspensions were made fresh tumor and non-tumorous tissue. Fourteen included whom twelve PDAC five samples obtained. These analyzed a nineteen marker panel on Aurora spectral flow cytometer. Furthermore, slides formalin-fixed paraffine PDACs eight additional stained markers by multispectral...
Trauma to the pancreas is rare but associated with significant morbidity. Currently available management guidelines are based on low-quality evidence and data long-term outcomes lacking. This study aimed evaluate clinical characteristics patient-reported for pancreatic injury.
Introduction: Effective (neo) adjuvant chemotherapy for cholangiocarcinoma is lacking due to chemoresistance and the absence of predictive biomarkers. Human equilibrative nucleoside transporter 1 (hENT1) has been described as a potential prognostic biomarker. In this study, rabbit-derived (SP120) murine-derived (10D7G2) antibodies detect hENT1 expression was compared in tissue samples patients with extrahepatic (ECC), value investigated three ECC cell lines. Methods: Tissues 71 chemonaïve...
Duodenal adenocarcinoma (DA) and intestinal-type papilla of Vater (it-PVA) are rare malignancies the gastrointestinal tract. Current therapeutic options translated nowadays from treatment strategies for patients with colorectal cancer due to histopathological similarities.To retrospectively investigate clinical outcome DA it-PVA.All it-PVA diagnosed between 2000 2017 were included at two academic centers in Netherlands. All histopathologically-confirmed or eligible inclusion. Clinical was...
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with 5-year survival of less than 10%. More knowledge the immune response developed in patients PDAC is pivotal to develop better combination therapies improve clinical outcome. In this study, we used mass cytometry time-of-flight undertake an in-depth characterization PBMCs from and examine differences healthy controls benign diseases biliary system or pancreas. Peripheral blood mononuclear cells disease are characterized by...